

Leisha A Emens

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6077587/publications.pdf>

Version: 2024-02-01

110
papers

13,273
citations

50170

46
h-index

33814

99
g-index

115
all docs

115
docs citations

115
times ranked

16375
citing authors

#	ARTICLE	IF	CITATIONS
1	Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 2108-2121.	13.9	3,097
2	Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 44-59.	5.1	826
3	The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies. <i>Cancer Immunology Research</i> , 2015, 3, 436-443.	1.6	631
4	Breast Cancer Immunotherapy: Facts and Hopes. <i>Clinical Cancer Research</i> , 2018, 24, 511-520.	3.2	567
5	Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 671-686.	1.1	564
6	Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer. <i>JAMA Oncology</i> , 2019, 5, 74.	3.4	557
7	Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape. <i>European Journal of Cancer</i> , 2017, 81, 116-129.	1.3	443
8	Recruitment of latent pools of high-avidity CD8+ T cells to the antitumor immune response. <i>Journal of Experimental Medicine</i> , 2005, 201, 1591-1602.	4.2	382
9	Targeting adenosine for cancer immunotherapy. , 2018, 6, 57.		379
10	Detection of Tumor <i>PIK3CA</i> Status in Metastatic Breast Cancer Using Peripheral Blood. <i>Clinical Cancer Research</i> , 2012, 18, 3462-3469.	3.2	296
11	PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. <i>Human Pathology</i> , 2016, 47, 52-63.	1.1	284
12	Antagonists of PD-1 and PD-L1 in Cancer Treatment. <i>Seminars in Oncology</i> , 2015, 42, 587-600.	0.8	259
13	Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer. <i>Cancer Discovery</i> , 2020, 10, 40-53.	7.7	219
14	Timed Sequential Treatment With Cyclophosphamide, Doxorubicin, and an Allogeneic Granulocyte-Macrophage Colony-Stimulating Factorâ€“Secreting Breast Tumor Vaccine: A Chemotherapy Dose-Ranging Factorial Study of Safety and Immune Activation. <i>Journal of Clinical Oncology</i> , 2009, 27, 5911-5918.	0.8	217
15	Chemoimmunotherapy: reengineering tumor immunity. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 203-216.	2.0	215
16	Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. <i>Lancet Oncology</i> , The, 2020, 21, 1283-1295.	5.1	213
17	Consensus Report of the National Cancer Institute Clinical Trials Planning Meeting on Pancreas Cancer Treatment. <i>Journal of Clinical Oncology</i> , 2009, 27, 5660-5669.	0.8	211
18	First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. <i>Annals of Oncology</i> , 2021, 32, 983-993.	0.6	205

#	ARTICLE	IF	CITATIONS
19	A Vascular Endothelial Growth Factor Receptor-2 Inhibitor Enhances Antitumor Immunity through an Immune-Based Mechanism. <i>Clinical Cancer Research</i> , 2007, 13, 3951-3959.	3.2	190
20	Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 3220-3228.	3.2	179
21	Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1005-1016.	3.0	171
22	Leveraging the Activity of Tumor Vaccines with Cytotoxic Chemotherapy. <i>Cancer Research</i> , 2005, 65, 8059-8064.	0.4	167
23	Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1597-1611.	1.1	144
24	Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice. <i>Cellular Immunology</i> , 2010, 263, 79-87.	1.4	137
25	The immune microenvironment of breast ductal carcinoma in situ. <i>Modern Pathology</i> , 2016, 29, 249-258.	2.9	119
26	A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice. <i>Cancer Immunology Research</i> , 2017, 5, 468-479.	1.6	117
27	OX40 Costimulation Synergizes with GM-CSF Whole-Cell Vaccination to Overcome Established CD8+ T Cell Tolerance to an Endogenous Tumor Antigen. <i>Journal of Immunology</i> , 2006, 176, 974-983.	0.4	102
28	Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers. <i>Gynecologic Oncology</i> , 2019, 154, 314-322.	0.6	101
29	HER-2/neu-Specific Monoclonal Antibodies Collaborate with HER-2/neu-Targeted Granulocyte Macrophage Colony-Stimulating Factor Secreting Whole Cell Vaccination to Augment CD8+ T Cell Effector Function and Tumor-Free Survival in Her-2/neu-Transgenic Mice. <i>Journal of Immunology</i> , 2003, 171, 2161-2169.	0.4	97
30	Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study. <i>Human Pathology</i> , 2013, 44, 2055-2063.	1.1	95
31	Chemoimmunotherapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2010, 16, 295-303.	1.0	91
32	GM-CSF-secreting vaccines for solid tumors: moving forward. <i>Discovery Medicine</i> , 2010, 10, 52-60.	0.5	85
33	Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer. <i>American Journal of Therapeutics</i> , 2005, 12, 243-53.	0.5	85
34	PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1733-1743.	3.0	83
35	The multikinase inhibitor Sorafenib reverses the suppression of IL-12 and enhancement of IL-10 by PGE2 in murine macrophages. <i>International Immunopharmacology</i> , 2010, 10, 1220-1228.	1.7	80
36	A Feasibility Study of Cyclophosphamide, Trastuzumab, and an Allogeneic GM-CSF-Secreting Breast Tumor Vaccine for HER2+ Metastatic Breast Cancer. <i>Cancer Immunology Research</i> , 2014, 2, 949-961.	1.6	77

#	ARTICLE	IF	CITATIONS
37	Antibody association with HER-2/neuâ€targeted vaccine enhances CD8+ T cell responses in mice through Fc-mediated activation of DCs. <i>Journal of Clinical Investigation</i> , 2008, 118, 1700-1711.	3.9	74
38	Immune targeting in breast cancer. <i>Oncology</i> , 2015, 29, 375-85.	0.4	72
39	Cancer vaccines: on the threshold of success. <i>Expert Opinion on Emerging Drugs</i> , 2008, 13, 295-308.	1.0	63
40	Racial disparities in the rate of cardiotoxicity of HER2â€targeted therapies among women with early breast cancer. <i>Cancer</i> , 2018, 124, 1904-1911.	2.0	59
41	A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 131, 915-924.	1.1	57
42	The follow-up of breast cancer. <i>Seminars in Oncology</i> , 2003, 30, 338-348.	0.8	56
43	Roadmap to a Better Therapeutic Tumor Vaccine. <i>International Reviews of Immunology</i> , 2006, 25, 415-443.	1.5	56
44	Development of Anti-Human Mesothelin-Targeted Chimeric Antigen Receptor Messenger RNAâ€Transfected Peripheral Blood Lymphocytes for Ovarian Cancer Therapy. <i>Human Gene Therapy</i> , 2018, 29, 614-625.	1.4	56
45	Development of [¹⁸ F]FPy-WL12 as a PD-L1 Specific PET Imaging Peptide. <i>Molecular Imaging</i> , 2019, 18, 153601211985218.	0.7	52
46	Clinical activity, safety and biomarker results from a phase Ia study of atezolizumab (atezo) in advanced/recurrent endometrial cancer (rEC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 5585-5585.	0.8	50
47	Targeting the programmed cell death-1 pathway in breast and ovarian cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2016, 28, 142-147.	0.9	47
48	Chemotherapy and tumor immunity: an unexpected collaboration. <i>Frontiers in Bioscience - Landmark</i> , 2008, 13, 249.	3.0	47
49	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer. , 2021, 9, e002597.		45
50	Digital Pathology Analysis Quantifies Spatial Heterogeneity of CD3, CD4, CD8, CD20, and FoxP3 Immune Markers in Triple-Negative Breast Cancer. <i>Frontiers in Physiology</i> , 2020, 11, 583333.	1.3	42
51	A Phase I Vaccine Safety and Chemotherapy Dose-Finding Trial of an Allogeneic GM-CSFâ€Secreting Breast Cancer Vaccine Given in a Specifically Timed Sequence with Immunomodulatory Doses of Cyclophosphamide and Doxorubicin. The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Baltimore, Maryland. <i>Human Gene Therapy</i> , 2004, 15, 313-337.	1.4	39
52	Tumor-associated macrophages and the tumor immune microenvironment of primary and recurrent epithelial ovarian cancer. <i>Human Pathology</i> , 2018, 74, 135-147.	1.1	39
53	A New Twist on Autologous Cancer Vaccines. <i>Cancer Biology and Therapy</i> , 2003, 2, 161-163.	1.5	36
54	Immunotherapy in Triple-Negative Breast Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 59-66.	1.0	36

#	ARTICLE	IF	CITATIONS
55	Cancer immunotherapy trials: leading a paradigm shift in drug development. , 2016, 4, 42.		35
56	PD-L1 expression and the immune microenvironment in primary invasive lobular carcinomas of the breast. <i>Modern Pathology</i> , 2017, 30, 1551-1560.	2.9	35
57	Breast cancer vaccines: Heeding the lessons of the past to guide a path forward. <i>Cancer Treatment Reviews</i> , 2020, 84, 101947.	3.4	35
58	Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer. , 2021, 9, e002100.		29
59	The evolving management of metastatic triple negative breast cancer. <i>Seminars in Oncology</i> , 2020, 47, 229-237.	0.8	28
60	Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab. , 2019, 7, 274.		26
61	Specific immunotherapy in ovarian cancer: a systematic review. <i>Immunotherapy</i> , 2016, 8, 1193-1204.	1.0	24
62	Sorafenib combined with HER-2 targeted vaccination can promote effective T cell immunity in vivo. <i>International Immunopharmacology</i> , 2017, 46, 112-123.	1.7	24
63	Changes in Breast Density and Circulating Estrogens in Postmenopausal Women Receiving Adjuvant Anastrozole. <i>Cancer Prevention Research</i> , 2011, 4, 1993-2001.	0.7	23
64	Association of Cancer Immunotherapy With Acute Macular Neuroretinopathy and Diffuse Retinal Venulitis. <i>JAMA Ophthalmology</i> , 2019, 137, 96.	1.4	22
65	Abstract GS2-10: Nimbus: A phase 2 trial of nivolumab plus ipilimumab for patients with hypermutated her2-negative metastatic breast cancer (MBC). <i>Cancer Research</i> , 2022, 82, GS2-10-GS2-10.	0.4	22
66	GV-1001, an injectable telomerase peptide vaccine for the treatment of solid cancers. <i>Current Opinion in Molecular Therapeutics</i> , 2007, 9, 490-7.	2.8	19
67	Augmenting the Potency of Breast Cancer Vaccines: Combined Modality Immunotherapy. <i>Breast Disease</i> , 2004, 20, 13-24.	0.4	18
68	Emerging combination immunotherapy strategies for breast cancer: dual immune checkpoint modulation, antibody-drug conjugates and bispecific antibodies. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 291-302.	1.1	18
69	Emerging immunotherapies in ovarian cancer. <i>Discovery Medicine</i> , 2015, 20, 97-109.	0.5	16
70	Feasibility Trial of Partial Breast Irradiation With Concurrent Dose-Dense Doxorubicin and Cyclophosphamide in Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 2816-2822.	0.8	15
71	Pathologic Complete Response to Preoperative Sequential Doxorubicin/Cyclophosphamide and Single-Agent Taxane With or Without Trastuzumab in Stage II/III HER2-Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2010, 10, 40-45.	1.1	15
72	Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 127, 153-162.	1.1	15

#	ARTICLE	IF	CITATIONS
73	Outcomes After Sentinel Lymph Node Biopsy and Radiotherapy in Older Women With Early-Stage, Estrogen Receptor-Positive Breast Cancer. <i>JAMA Network Open</i> , 2021, 4, e216322.	2.8	15
74	Dynamics of tumor-associated macrophages in a quantitative systems pharmacology model of immunotherapy in triple-negative breast cancer. <i>IScience</i> , 2022, 25, 104702.	1.9	15
75	Cancer vaccines: an old idea comes of age. <i>Cancer Biology and Therapy</i> , 2003, 2, S161-8.	1.5	14
76	Impact of Anti-HER2 Treatments Combined With Atezolizumab on the Tumor Immune Microenvironment in Early or Metastatic Breast Cancer: Results From a Phase Ib Study. <i>Clinical Breast Cancer</i> , 2021, 21, 539-551.	1.1	13
77	Cancer Vaccines in Combination with Multimodality Therapy. , 2005, 123, 227-245.		13
78	To Live or Not to Live-THAT Depends on GAGE?. <i>Cancer Biology and Therapy</i> , 2002, 1, 387-389.	1.5	12
79	Nimbus: A phase II study of nivolumab plus ipilimumab in metastatic hypermutated HER2-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS1115-TPS1115.	0.8	12
80	Cancer Vaccines: An Old Idea Comes of Age. <i>Cancer Biology and Therapy</i> , 2003, 2, 160-167.	1.5	11
81	Current and emerging biologic therapies for triple negative breast cancer. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 591-602.	1.4	11
82	GM-CSF-secreting vaccines for solid tumors. <i>Current Opinion in Investigational Drugs</i> , 2009, 10, 1315-24.	2.3	11
83	Invasive Lobular Carcinoma of the Male Breast: A Rare Histology in an Uncommon Disease. <i>Breast Care</i> , 2009, 4, 36-38.	0.8	10
84	Reflex Estrogen Receptor/Progesterone Receptor/Human Epidermal Growth Factor Receptor 2 (ER/PR/Her2) Analysis of Breast Cancers in Needle Core Biopsy Specimens Dramatically Increases Health Care Costs. <i>American Journal of Surgical Pathology</i> , 2015, 39, 939-947.	2.1	9
85	Re-purposing cancer therapeutics for breast cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 1299-1305.	2.0	8
86	Toward a breast cancer vaccine: work in progress. <i>Oncology</i> , 2003, 17, 1200-11; discussion 1214, 1217-8.	0.4	8
87	Reflex Estrogen Receptor (ER) and Progesterone Receptor (PR) Analysis of Ductal Carcinoma In Situ (DCIS) in Breast Needle Core Biopsy Specimens. <i>American Journal of Surgical Pathology</i> , 2016, 40, 1090-1099.	2.1	7
88	Predictive Biomarkers: Progress on the Road to Personalized Cancer Immunotherapy. <i>Journal of the National Cancer Institute</i> , 2021, , .	3.0	7
89	Survivin ¹ Cancer. <i>Cancer Biology and Therapy</i> , 2004, 3, 180-183.	1.5	6
90	It's TIME for a biomarker-driven approach to cancer immunotherapy. , 2016, 4, 43.		6

#	ARTICLE	IF	CITATIONS
91	A New Landscape of Testing and Therapeutics in Metastatic Breast Cancer. <i>Surgical Pathology Clinics</i> , 2022, 15, 105-120.	0.7	6
92	Towards a therapeutic breast cancer vaccine: the next steps. <i>Expert Review of Vaccines</i> , 2005, 4, 831-841.	2.0	4
93	A phase 1 study of TPST-1120 as a single agent and in combination with nivolumab in subjects with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3005-3005.	0.8	4
94	The dawn of immunotherapy for breast cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2019, 17, 332-335.	0.3	3
95	A Phase I Toxicity and Feasibility Trial of Sequential Dose-Dense Induction Chemotherapy with Doxorubicin, Paclitaxel, and 5-Fluorouracil Followed by High Dose Consolidation for High-Risk Primary Breast Cancer. <i>Breast Cancer Research and Treatment</i> , 2002, 76, 145-156.	1.1	2
96	New findings about endocrine therapy for breast cancer. <i>Breast</i> , 2003, 12, 368-372.	0.9	2
97	STING signaling: a key to therapeutic tumor immunity. <i>Immunotherapy</i> , 2018, 10, 729-731.	1.0	2
98	Robust antigen-specific CD8 T cell tolerance to a model prostate cancer neoantigen. <i>Oncolmmunology</i> , 2020, 9, 1809926.	2.1	2
99	317â€¦A phase 1/1b study of SBT6050, a HER2-directed monoclonal antibody conjugated to a toll-like receptor 8 agonist, in subjects with advanced HER2-expressing solid tumors. , 2020, , .		2
100	Impact of steroid premedication on atezolizumab (atezo)-induced immune cell activation: A comparative analysis of IMpassion130 and IMpassion131 peripheral blood mononuclear cells (PBMCs).. <i>Journal of Clinical Oncology</i> , 2022, 40, 1083-1083.	0.8	2
101	Chemotherapyâ€™A Viable Partner for Cancer Immunotherapy?. <i>JAMA Oncology</i> , 2015, 1, 1095.	3.4	1
102	Cytokine profiling of tumor-infiltrating T lymphocytes by flow cytometry. <i>Methods in Enzymology</i> , 2020, 631, 1-20.	0.4	1
103	Mechanisms of action and acquired resistance to atezolizumab plus <i>nab</i> -paclitaxel in metastatic triple-negative breast cancer (mTNBC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 1078-1078.	0.8	1
104	Introducing the clinical trials monitor: a new section of the journal for immunotherapy of cancer. , 2015, 3, 49.		0
105	A Novel Approach to Journal Club Designed to Immerse Trainees in a Peer-Review Process to Critically Evaluate Oncology Manuscripts. <i>Medical Science Educator</i> , 2016, 26, 273-274.	0.7	0
106	Abstract PS1-10: Outcomes after sentinel lymph node biopsy and radiation therapy in women over 70 years old with ER+, HER2-, clinically node negative breast cancer. , 2021, , .		0
107	Multi-center randomized study of pembrolizumab/carboplatin versus carboplatin alone in patients with chest wall disease from breast cancer: TBCRC 044.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS1111-TPS1111.	0.8	0
108	Patterns and Predictors of First-Line Taxane Use in Patients with Metastatic Triple-Negative Breast Cancer in US Clinical Practice. <i>Current Oncology</i> , 2021, 28, 2741-2752.	0.9	0

#	ARTICLE	IF	CITATIONS
109	Abstract OT1-12-02: Trial in progress: Phase 2, open-label study to evaluate the safety and efficacy of praluzatamab raptansine in metastatic HER2 non-amplified breast cancer as monotherapy and combination with pacmilimab. Cancer Research, 2022, 82, OT1-12-02-OT1-12-02.	0.4	0
110	Quiescent cancer cells: Therapeutic targets to overcome immunotherapy resistance?. Med, 2022, 3, 358-360.	2.2	0